Since early 2014, more than 30 states in the US have introduced so-called "Right to Try" bills in the hopes of allowing terminally ill patients to access experimental and potentially life-saving treatments. Download the PDF to glance at the Right To Try movement in the US.
Artificial intelligence could herald a new era for drug development but caution remains about how revolutionary its impact will actually be
The US FDA’s recommended approval of Novartis’ CAR-T cell therapy pushes the product closer to being the first treatment of its kind available on the market.
Despite some in the market choosing to shut down certain departments, many in the pharma industry are embarking on expansions. Ireland is expected to see a lot of growth
At the recent CRISPR summit conference Pharma IQ spoke to Ben Borgo of Agilent Technologies about the future of the gene editing technique.
Last summer, the Zika virus outbreak triggered a worldwide health alert. Today, pathogen is a discovery priority as there is still no treatment in existence to combat the disease
The Reputation Institute has revealed the top 10 most reputable pharma companies as voted by the general public. In a surprising result, AstraZeneca and GSK both failed to make the top 10.
Amid pressure to limit discovery losses and be more ethically responsible, the pharma industry is slowly bowing to the growing weight of evidence to find alternatives to testing on animals.
Astrazeneca and its biologics arm, Medimmune, advance in the R&D race as three new oncology drug candidates see promising developments
New research from The George Institute for Global Health discovers that despite being prescribed more often, the drug pregabalin was no better than a placebo